| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.STR.26.7.1183 |
| P698 | PubMed publication ID | 7541572 |
| P2093 | author name string | K R Lees | |
| K W Muir | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | magnesium | Q660 |
| placebo | Q269829 | ||
| magnesium sulfate | Q18212318 | ||
| magnesium sulfate | Q288266 | ||
| P304 | page(s) | 1183-1188 | |
| P577 | publication date | 1995-07-01 | |
| P1433 | published in | Stroke Journal | Q7624282 |
| P1476 | title | A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. | |
| P478 | volume | 26 |
| Q37282443 | Acute decrease in serum magnesium level after ischemic stroke may not predict decrease in neurologic function |
| Q36045223 | Clinical trials for cytoprotection in stroke |
| Q34566325 | Current status of neuroprotective agents in the treatment of acute ischemic stroke |
| Q24804442 | Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial |
| Q74598571 | Does neuroprotection improve stroke outcome? |
| Q40834591 | Drug therapy for acute ischaemic stroke: risks versus benefits |
| Q51297225 | Effect of magnesium sulphate in experimental spinal cord injury: evaluation with ultrastructural findings and early clinical results. |
| Q46941574 | Effects of magnesium sulfate administration during hypoxia on Ca(2+) influx and IP(3) receptor modification in cerebral cortical neuronal nuclei of newborn piglets |
| Q48608628 | Effects of polyethylene glycol and magnesium sulfate administration on clinically relevant neurological outcomes after spinal cord injury in the rat. |
| Q24248015 | Excitatory amino acid antagonists for acute stroke |
| Q37220928 | Experimental neuronal protection in cerebral ischaemia Part II: Potential neuroprotective drugs |
| Q30664114 | Extracellular magnesium regulates nuclear and perinuclear free ionized calcium in cerebral vascular smooth muscle cells: possible relation to alcohol and central nervous system injury |
| Q48406416 | Hypomagnesemia after aneurysmal subarachnoid hemorrhage |
| Q43596512 | Increased extracellular magnesium modulates proliferation in fetal neural cells in culture |
| Q48522853 | Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. |
| Q35648103 | Investigational therapies for ischemic stroke: neuroprotection and neurorecovery |
| Q33539477 | Limiting neurological damage after stroke: a review of pharmacological treatment options |
| Q39451085 | Low levels of serum ionized magnesium are found in patients early after stroke which result in rapid elevation in cytosolic free calcium and spasm in cerebral vascular muscle cells |
| Q58776312 | Magnesium Protects in Episodes of Critical Perfusion after Aneurysmal SAH |
| Q48913482 | Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial |
| Q34458392 | Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness |
| Q36256094 | Magnesium neuroprotection is limited in humans with acute brain injury |
| Q45109668 | Magnesium sulfate attenuates peroxide-induced vasoconstriction in the human placenta |
| Q48339039 | Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial |
| Q24250098 | Magnesium sulfate for term infants following perinatal asphyxia |
| Q50494271 | Magnesium sulfate treatment in experimental spinal cord injury: emphasis on vascular changes and early clinical results. |
| Q36811695 | Magnesium treatment for neuroprotection in ischemic diseases of the brain. |
| Q35159997 | Magnesium: potential roles in neurovascular disease |
| Q40440033 | Management following resuscitation from cardiac arrest: recommendations from the 2003 Rocky Mountain Critical Care Conference |
| Q33904379 | Management of cerebral vasculopathy in children with sickle cell anaemia |
| Q73425135 | Mg2+ modulates membrane lipids in vascular smooth muscle: a link to atherogenesis |
| Q35096123 | Molecular pathways in cerebral ischemia: cues to novel therapeutic strategies. |
| Q41241794 | Neurochemical mechanisms in brain injury and treatment: a review |
| Q48176970 | Neuroprotection after major cardiovascular surgery. |
| Q33747433 | Neuroprotection in acute ischaemic stroke. II: Clinical potential |
| Q48913490 | Neuroprotective therapy for acute ischaemic stroke: down, but not out. |
| Q48358481 | Postinjury magnesium sulfate treatment is not markedly neuroprotective for striatal medium spiny neurons after perinatal hypoxia/ischemia in the rat. |
| Q37222956 | Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial. |
| Q36180766 | Role of magnesium sulfate in neuroprotection in acute ischemic stroke |
| Q44213576 | Serum levels of trace elements and heavy metals in patients with acute hemorrhagic stroke |
| Q41513689 | The rationale for new therapies in acute ischaemic stroke |
| Q39427028 | The role of magnesium sulfate in the intensive care unit |
| Q34977035 | Therapeutic approaches to cerebral vasospasm complicating ruptured aneurysm |
| Q40890524 | Trends and Future Developments in the Pharmacological Treatment of Acute Ischaemic Stroke |
| Q24236792 | Vasoactive drugs for acute stroke |
| Q30943615 | Vasoactive drugs for acute stroke. |
| Q30620998 | What animal models have taught us about the treatment of acute stroke and brain protection |
| Q80171015 | [Effect of combination therapy with hypothermia, magnesium and tirilazad in an experimental model of diffuse cerebral ischemia] |
Search more.